Slide 1: Memphasys' Investor Presentation (ASX Release)
ASX Release For personal use only MEMPHASYS’ INVESTOR PRESENTATION Sydney, Thursday 24 November 2016 Memphasys Limited (ASX: MEM) is providing an investor presentation entitled ‘New Horizons in Artificial Reproduction’. The presentation focusses on the Company’s SpermSep business and provides invest
Slide 2: New horizons in artificial reproduction
For personal use only New horizons in artificial reproduction Alison Coutts | Executive Chairman November 2016 www.memphasys.com
Slide 3: Disclaimer
Disclaimer For personal use only This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell Memphasys securities or other products should be made only after seeking appropriate financial advice. Reliance should not
Slide 4: An Australian bio-separations company
For personal use only An Australian bio-separations company Separating high value components (e.g. sperm) from biological fluids for global markets using proprietary membranes (size) and electrophoresis (charge). Original SpermSep prototype device November 2016 www.memphasys.com 3
Slide 5: Corporate and investment summary
Corporate and investment summary For personal use only A unique device for CORPORATE SNAPSHOT KEY selecting the best, most viable sperm for ASX Code: MEM ASSET artificial reproduction in humans (IVF) and “SpermSep” Shares on issue: 569m animals Sector: Biotech & Life Science improving outcomes f
Slide 6: Key asset: SpermSep technology
Key asset: SpermSep technology • SpermSep can accurately separate the best sperm for fertility treatments such as IVF For personal use only • It uses a bench-top instrument with disposable, single-use cartridges to separate sperm from semen samples • Sample is loaded into the cartridge and the sperm
Slide 7: Key asset: SpermSep technology
Key asset: SpermSep technology For personal use only • To perform IVF the most viable sperm must be separated from the semen sample • Current sperm separation techniques (“DGC” &“Swim Up”) have limitations: – DGC increases physical and DNA damage from oxidative stress to the extracted sperm – Swim U
Slide 8: SpermSep's Inventor: Prof John Aitken
SpermSep’s Inventor: Prof John Aitken Professor Aitken is a world renowned expert in reproductive biology For personal use only and the inventor the SpermSep technology. As he explains: “SpermSep selects the best sperm from ejaculate, which makes the process of sperm separation for in vitro fertilis
Slide 9: The global market for IVF treatments
The global market for IVF treatments For personal use only Couples with fertility issues ~50 million Australian couples seeking IVF: 1 in 6 Global IVF Cycles/year ~15 million 570,000 in Australia clinic IVF babies/year ~350,000 10,500 in Australia business Numbers of IVF clinics ~3,000 EU is largest
Slide 10: SpermSep: Addressing male infertility – an unmet medical need
SpermSep: Addressing male infertility – an unmet medical need For personal use only Male infertility: • a major issue for over 40% of infertile couples • increasing globally in developed and developing world • highly correlated with age and affects fertility in a third of men over 40 • adversely aff
Slide 11: Age and DNA damage play a major role
Age and DNA damage play a major role For personal use only Sperm with highly damaged DNA Log percent highly damaged DNA (%) (%; P < 0.0001) 25 5 20 4 15 3 10 2 05 1 0 0 20- 36- 20 25 30 35 40 45 50 55 60 35 57 Age (years) Age (years) Source: Reproduced with permission from The University of Newcastl
Slide 12: Effects of age and DNA damage
Effects of age and DNA damage For personal use only Bipolar disease Autism Mutation rate Odds ration Odds ratio Number of de novo mutations called 10 Proband parent of autistic case 2.5 120 Autism 8 2.0 100 6 Autism 1.5 80 1.0 4 60 0.5 2 40 0 0 20- 25- 30- 35- 40- 45- 50+ 15- 30- 40- 50+ 15 20 25 30
Slide 13: Business model – Strategy to create value
Business model – Strategy to create value • We are developing a second-generation clinical SpermSep device For personal use only new biocompatible hydrogel polymer membrane established optimising operating parameters of a low- cost, single-use sterile cartridge • Now ready to finalise design and bui
Slide 14: Comparison with current treatments
Comparison with current treatments For personal use only • Swim Up and DGC are the current techniques to process sperm for human IVF • Both are lab separation processes using multiple washing and centrifuging steps • These processes are not only time consuming and laborious but also impart DNA damag
Slide 15: SpermSep: Path to market
SpermSep: Path to market For personal use only • Develop up to 30 fast prototype next gen SperSep devices for KOL clinical assessment/ adoption/ endorsement • Conduct in-vitro clinical trials of these devices in leading global IVF centres under leadership Prof John Aitken (Uni. of Newcastle) – We ex
Slide 16: SpermSep: Development milestones
SpermSep: Development milestones For personal use only • In-depth regulatory plan is in development • Advice received is that in-vivo trials (embryo fertilisation and tracking to birth) will not be required for regulatory approval • Regulatory approval to be based on: – demonstration of device’s ele
Slide 17: Key milestones and indicative funding required
Key milestones and indicative funding required For personal use only Milestone Months Cumulative $m 1 First 3 prototypes for performance validation study 6 1.5 2 Recruitment of approx. 20 international KOLs* to participate in Clinical 9 2.1 Assessment project 3 Production Prototypes built for Clinic
Slide 18: Intellectual property & collaborations
Intellectual property & collaborations For personal use only Patents • Memphasys has the following patents: – its electrophoresis membrane separation process – Its SpermSep cartridge design for sperm separation – the newly-developed polymer membranes for various biological separations • It has an ex
Slide 19: Investment summary
Investment summary For personal use only • Powerful, well protected Australian technology already proven to work • Global market potential in fast growing healthcare sector • Targeting use in both mature and developing country markets • Initial focus is human IVF: very high unmet clinical need for m
Slide 20: Contact details
For personal use only Contact details Alison Coutts Executive Chairman 30-32 Richmond Road Homebush NSW 2140 Australia Tel: +61 (2) 8415 7300 alison.coutts@memphasys.com www.memphasys.com ACN 120 047 556 November 2016 www.memphasys.com 19
Slide 21: Appendix: Product pipeline
Appendix: Product pipeline Equine market – the next application For personal use only • Thoroughbred racehorse breeders not allowed to use artificial reproduction • Initial focus will be standard bred horse market* • Australia is third largest global market • Investigating improvements to equine rep
Slide 22: Appendix: Shareholding in PrIME Biologics Pte Ltd
Appendix: Shareholding in PrIME Biologics Pte Ltd For personal use only • In 2014 Memphasys spun out PrIME Biologics (“PrIME”) in Singapore and agreed to take principal responsibility for payment of a debt to a third party as part of the agreement to receive B class non-voting shares in PrIME. – The